Pages that link to "Q70756110"

The following pages link to Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study (Q70756110):

Displaying 49 items.

• Phosphodiesterase III inhibitors for heart failure (Q24244978) (← links)
• Mechanisms of altered Ca²⁺ handling in heart failure (Q27012758) (← links)
• Current and novel pharmacologic approaches in advanced heart failure (Q33688965) (← links)
• Shifts in mortality curves: saving or extending lives? . (Q33759118) (← links)
• Vasopressin: a therapeutic target in congestive heart failure? (Q33817147) (← links)
• The role of exercise testing in the evaluation and management of heart failure (Q33823518) (← links)
• Rethinking Phase II Clinical Trial Design in Heart Failure (Q34377514) (← links)
• Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations (Q35120861) (← links)
• Nesiritide for acute decompensated heart failure: does the benefit justify the risk? (Q36806952) (← links)
• Predicting survival in heart failure (Q36806963) (← links)
• Six minute walk test: a simple and useful test to evaluate functional capacity in patients with heart failure (Q37094605) (← links)
• Protein kinase C, an elusive therapeutic target? (Q37141320) (← links)
• Drug and Device Effects on Peak Oxygen Consumption, 6-Minute Walk Distance, and Natriuretic Peptides as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction (Q37894492) (← links)
• Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency (Q38806549) (← links)
• New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment (Q38955252) (← links)
• Protein kinase C and cardiac dysfunction: a review (Q39432092) (← links)
• Medical therapy and prognosis in chronic heart failure. Lessons from clinical trials. (Q39477465) (← links)
• Exercise testing in heart failure. A critical review (Q40393250) (← links)
• Is there a role for positive inotropic agents in congestive heart failure: focus on mortality (Q40599753) (← links)
• Novel drugs and current therapeutic approaches in the treatment of heart failure (Q41177950) (← links)
• Pharmacotherapy for Systolic Dysfunction: A Review of Randomized Clinical Trials (Q41645917) (← links)
• Statistical issues and analysis of mortality and morbidity randomized clinical trials in congestive heart failure (Q41675581) (← links)
• Restoring Function in Failing Hearts: The Effects of Beta Blockers (Q41732517) (← links)
• Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach (Q41845098) (← links)
• Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure (Q42671091) (← links)
• Analysis of the cilostazol safety database (Q43659958) (← links)
• Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan (Q43812970) (← links)
• Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan (Q44193438) (← links)
• Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure (Q44505481) (← links)
• Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment. (Q47121794) (← links)
• The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure (Q47158526) (← links)
• Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review (Q49196618) (← links)
• Functions of PDE3 Isoforms in Cardiac Muscle (Q50132075) (← links)
• A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) (Q53593952) (← links)
• Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. (Q54015370) (← links)
• Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure (Q57822514) (← links)
• Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors (Q70880316) (← links)
• Recent advances in cardiology (Q72421263) (← links)
• Acronyms for heart failure trials (Q72456229) (← links)
• Vasodilators in the treatment of pediatric heart failure (Q73292088) (← links)
• Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure (Q73500776) (← links)
• Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan (Q73599559) (← links)
• Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators (Q73858782) (← links)
• Current and novel pharmacologic approaches in advanced heart failure (Q74660339) (← links)
• Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers (Q77802846) (← links)
• Surrogate end points in heart failure (Q78032634) (← links)
• [Drug prospects in the treatment of heart insufficiency] (Q78851641) (← links)
• Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure (Q89071685) (← links)
• Phase II Trials in Drug Development and Adaptive Trial Design (Q91943657) (← links)